Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Novartis explore novel approaches to disease modelling and organoid technology

SMi Group
Posted on: 10 Nov 16
Novartis explore novel approaches to disease modelling and organoid technology

Leading pharmaceutical innovators Novartis have joined the expert speaker line-up for SMi Group’s inaugural conference on 3D Cell Culture which takes place on the 22nd and 23rd of February 2017 in London.

Novartis will be present two case studies at the event, with a dedicated focus on novel approaches to disease modelling and organoid technology.

Researcher Max Salick will present a case study on CRISPR engineered organoids for modelling genetic and infectious brain diseases. The presentation will explain how recent genetic advances allow rapid production of isogenically-controlled disease stem cell lines which manifest in cerebral organoids and, similarly, in the developing human brain. Max will also explore advanced imaging and sequencing methods that aid in investigation for disease and treatment effects, as well as similar engineering techniques that allow precise examination of interactions between specific proteins and infectious diseases.

On Day Two, Scientist Olaf Galuba will present a case study on how mouse intestinal crypt cultures have been adapted to enable high throughput screening. He will also discuss the challenges facing the implementation of such assays such as handling Matrigel, the limits of miniaturisation and reproducibility.

Other case studies on 3D Cell Culture technologies and innovations will be presented by MHRA, Sanofi Aventis, AstraZeneca, Novartis, Lonza, GSK, TissUse and many more. A detailed two-day agenda is available to download on the event website.

In line with this, GE Healthcare Life Sciences will host an exclusive half-day pre-conference workshop on bio-printing on 21st February 2017.

With a focus on clinical successes and emerging technologies, 3D Cell Culture will highlight how this pivotal technique has revolutionised drug discovery and toxicity screening, as well as how it is emerging as an invaluable tool in stem-cell research and regenerative medicine.

For more details about the conference and registration information, visit

3D Cell Culture
22 & 23 February 2017
Copthorne Tara Hotel, London, UK

---end ---

Contact Information:

For sponsorship and exhibition queries please contact Alia Malick at For delegate queries please contact Matthew Apps at For media queries please contact Honey de Gracia at

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

For more information:

Editor's Details

Honey de Gracia
SMi Group

Last updated on: 10/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.